10-Q: Upstream Bio Reports Positive CRSwNP Data, Advances Pipeline

Upstream Bio, a clinical-stage biopharmaceutical company, reported positive top-line results for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) and advanced its severe asthma and COPD programs, while incurring increased net losses.

Summary

• Upstream Bio is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders.
• The company's lead product candidate, verekitug, is a monoclonal antibody targeting the Thymic Stromal Lymphopoietin (TSLP) receptor, currently in Phase 2 trials for severe asthma, CRSwNP, and COPD.
• Positive top-line results for verekitug in CRSwNP were reported in September 2025.
• Enrollment for the severe asthma Phase 2 trial was completed in June 2025, with top-line data anticipated in the first quarter of 2026.
• A Phase 2 COPD trial for verekitug was initiated in July 2025.
• Net loss for the nine months ended September 30, 2025, significantly increased to $101.0 million, compared to $41.6 million for the same period in 2024.
• Research and development expenses more than doubled to $96.6 million for the nine months ended September 30, 2025, up from $41.2 million in the prior year, driven by increased clinical trial activity and manufacturing costs for Phase 3 material.
• General and administrative expenses also rose to $19.7 million for the nine months ended September 30, 2025, from $12.0 million in 2024.
• As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $372.4 million, which is expected to fund operations through 2027.
• The accumulated deficit reached $291.8 million as of September 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant clinical progress (positive CRSwNP data, asthma enrollment completion, COPD initiation) and a solid cash runway through 2027. However, this is tempered by substantially increased net losses and cash burn, and the inherent high risks of a single-product clinical-stage biotech, including the need for future financing and intense competition.

Positives

• Reported positive top-line results for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) in September 2025.
• Completed enrollment in the severe asthma Phase 2 trial in June 2025, with top-line data expected in Q1 2026.
• Initiated the Phase 2 COPD trial in July 2025, expanding the pipeline's reach.
• Maintained a strong liquidity position with $372.4 million in cash, cash equivalents, and short-term investments, projected to fund operations through 2027.
• Collaboration revenue increased to $2.2 million for the nine months ended September 30, 2025, from $1.8 million in the prior year.

Negatives

• Net loss significantly widened to $101.0 million for the nine months ended September 30, 2025, compared to $41.6 million for the same period in 2024.
• Accumulated deficit grew to $291.8 million as of September 30, 2025.
• Cash used in operating activities increased substantially to $102.6 million for the nine months ended September 30, 2025, from $39.6 million in the prior year, indicating a higher cash burn rate.
• Research and development expenses more than doubled, reflecting the high cost of advancing clinical programs and manufacturing for later-stage trials.
• The company relies on a single product candidate, verekitug, making it highly dependent on its success.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and has incurred significant financial losses since inception, anticipating continued losses for the foreseeable future.
• Additional funding will be required to finance operations beyond 2027; inability to raise capital on acceptable terms could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Verekitug is the only product candidate, and the company is dependent on a third party having accurately generated, collected, and reported data from certain preclinical studies.
• The successful development of pharmaceutical products involves a lengthy, expensive, and highly uncertain process.
• Regulatory approval processes (FDA, EMA, European Commission) are lengthy, time-consuming, and unpredictable, potentially leading to substantial harm if approval is not obtained or is significantly delayed.
• Verekitug represents a novel approach to inflammatory diseases, making its likelihood of success and development timing/cost difficult to predict.
• Clinical trials may fail to replicate positive results from earlier preclinical studies or clinical trials, hindering development and commercialization.
• Unexpected costs or delays in completing development and commercialization could prevent achievement of projected goals.
• Verekitug or future product candidates may cause undesirable side effects, delaying or preventing regulatory approval or limiting commercial profile.
• Even if approved, verekitug may fail to achieve market acceptance by physicians, patients, and third-party payors.
• Competitive products from major pharmaceutical and biotechnology companies (e.g., Sanofi, Regeneron, AstraZeneca, Amgen) may reduce or eliminate commercial opportunity.
• Expected organizational expansion may lead to difficulties in managing growth, disrupting operations.
• Ability to develop verekitug and future growth depends on attracting, hiring, and retaining key personnel.
• Reliance on third parties (CROs, CMOs) to conduct clinical trials and manufacturing increases risks of unsatisfactory performance, delays, or supply issues.
• Intellectual property protection may be inadequate or difficult to enforce, and the company may be sued for infringement.
• Information technology systems, or those of third parties, may fail or suffer security breaches, impacting business operations and data integrity.
• Geopolitical actions, such as the BIOSECURE Act targeting Chinese biotechnology companies like WuXi, could materially impact manufacturing agreements and supply chains.
• Changes in funding for, or disruptions to the staffing and operations of, the FDA and other government agencies could hinder timely product development and commercialization.
• Relationships with healthcare professionals and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws, potentially leading to sanctions or penalties.
• Coverage and reimbursement for verekitug may be limited or unavailable, making profitable sales difficult.
• Ongoing healthcare legislative and regulatory reform measures (e.g., Inflation Reduction Act, One Big Beautiful Bill Act) may adversely affect business and results of operations.
• The increasing use of social media platforms presents new risks and challenges related to communication, adverse event reporting, and regulatory compliance.
• Artificial intelligence presents risks and challenges, including security risks to confidential information and an uncertain regulatory environment, potentially leading to reputational harm or liability.
• Changes in patent law could diminish the value of patents, impairing the ability to protect technologies.
• The company's ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes or regulatory changes.

Future Outlook

The company anticipates continued significant net operating losses for the foreseeable future as it advances verekitug through clinical trials and seeks regulatory approvals. Expenses are expected to increase substantially with further clinical development, manufacturing for commercial supplies, expansion of personnel, and costs associated with operating as a public company. Existing cash, cash equivalents, and short-term investments are believed to be sufficient to fund operating expenses and capital expenditure requirements through 2027, but additional financing will be needed thereafter to support continuing operations and growth strategy.

Management Comments

• We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
• We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
• Preclinical and clinical data to date demonstrate verekitugs highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients.
• We reported positive top-line results in CRSwNP in September 2025.
• We completed enrollment in our severe asthma Phase 2 trial in June 2025 and anticipate reporting top-line data from this trial in the first quarter of 2026.
• We initiated our Phase 2 COPD trial in July 2025.
• Our experienced team is committed to maximizing verekitugs unique attributes to address the substantial unmet needs for patients underserved by todays standard of care.
• Based on our current operating plan, we believe that our existing cash and cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements through 2027.

Industry Context

Upstream Bio operates in the highly competitive biopharmaceutical industry, specifically targeting inflammatory diseases and severe respiratory disorders. Its lead candidate, verekitug, is positioned as the only known TSLP receptor antagonist in clinical development, differentiating it from other TSLP pathway therapies like dupilumab and tezepelumab. The industry faces increasing scrutiny regarding data privacy (e.g., EU GDPR, UK GDPR, U.S. state laws, and the U.S. Department of Justice's rule on sensitive personal data transfers to 'countries of concern'), AI regulation (e.g., EU AI Act), and drug pricing (e.g., Inflation Reduction Act, OBBBA). Geopolitical tensions, such as those with China, also pose risks to supply chains and manufacturing partners like WuXi Biologics.

Comparison to Industry Standards

• Verekitug is highlighted as the 'only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP)', suggesting a unique market position compared to other TSLP pathway modulators like dupilumab and tezepelumab.
• The company's significant net losses and high R&D expenses are typical for a clinical-stage biopharmaceutical company, reflecting the substantial investment required for drug development before commercialization.
• The reliance on third-party CROs and CMOs for clinical trials and manufacturing is a common industry practice, but also introduces risks related to control, compliance, and supply chain disruptions.
• The company's decision not to run head-to-head clinical trials against current standards of care for verekitug is a strategic choice that may make it more challenging to demonstrate superior efficacy or safety in a competitive market, where companies like Sanofi, Regeneron, AstraZeneca, and Amgen have established products.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any litigation or legal proceedings that, in management's opinion, are probable to have a material adverse effect on its business. However, litigation can have an adverse impact due to defense and settlement costs, and diversion of management resources.

Related Party Transactions

• The company entered into the Maruho Agreement in October 2021. Through the IPO date, Maruho was considered a related party due to co-founding and board representation. Since the IPO in October 2024, Maruho is no longer considered a related party as they no longer have board representation.
• During the nine months ended September 30, 2025, the company received $2.1 million in cost reimbursements from Maruho, compared to $1.2 million in the prior year.
• Collaboration revenue from Maruho was $2.2 million and $1.8 million for the nine months ended September 30, 2025 and 2024, respectively.
• As of September 30, 2025, $0.7 million was in accounts receivable from Maruho for reimbursable expenses.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future capital raises and stock incentive plans. The stock price is highly volatile and sensitive to clinical trial results and financial performance. Significant losses and cash burn could impact long-term value, while positive clinical data could drive appreciation.
• **Employees:** Benefit from stock incentive plans (2024 Plan, 2024 ESPP) and increased headcount, but face intense competition for qualified personnel in the biotechnology industry.
• **Customers (future):** Potential for new treatments for severe asthma, CRSwNP, and COPD, addressing unmet medical needs. However, market acceptance depends on efficacy, safety, pricing, and reimbursement.
• **Suppliers/Contractors (CROs, CMOs):** The company's reliance on third parties for clinical trials and manufacturing provides business for these entities, but also exposes the company to risks if these parties do not perform satisfactorily or face geopolitical restrictions (e.g., WuXi Biologics).
• **Creditors:** The company's need for future financing and its accumulated deficit indicate reliance on external capital, which could affect its creditworthiness.

Next Steps

• Report top-line data from the severe asthma Phase 2 trial in the first quarter of 2026.
• Continue to conduct ongoing clinical trials for verekitug in severe asthma, CRSwNP, and COPD.
• Initiate and complete additional clinical trials of verekitug in new indications or patient populations.
• Seek regulatory approvals for verekitug in indications where clinical trials are successful.
• Manufacture, or have manufactured, clinical and commercial supplies of verekitug.
• Attract, hire, and retain additional clinical, scientific, and management personnel.
• Implement operational, financial, and management information systems.
• Add quality control, quality assurance, legal, compliance, and other groups to support operations.
• Obtain, maintain, protect, expand, and enforce the intellectual property portfolio.
• Establish a sales, marketing, and distribution infrastructure, either independently or through partnerships, if verekitug is approved.

Key Dates

Recommendation

Upstream Bio presents a mixed financial picture. While the company has made significant clinical progress with positive CRSwNP data, completed asthma trial enrollment, and initiated a COPD trial for its sole product candidate, verekitug, it also reported substantially increased net losses and cash burn. The strong cash position, expected to last through 2027, provides a runway for continued development. However, the inherent risks of a clinical-stage biotech, including the uncertainty of regulatory approvals, intense competition, and the need for future capital raises, warrant a cautious approach. The unique mechanism of action for verekitug is a positive differentiator, but the lack of head-to-head trials against established competitors adds a layer of risk. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor upcoming clinical data and the company's ability to secure future financing and navigate the competitive landscape.

Keywords

Biopharmaceutical, Clinical-stage, Inflammatory diseases, Severe asthma, CRSwNP, COPD, Verekitug, TSLP receptor antagonist, Phase 2 clinical trials, Drug development, SEC filing, Biotech, Monoclonal antibody, Respiratory disorders, Financial results